Cervical Cancer

Chicago, IL—The addition of the PD-1 inhibitor pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) resulted in a substantial and clinically meaningful improvement in overall survival (OS) in patients with persistent, recurrent, or metastatic cervical cancer, according to the final OS analysis of the phase 3 KEYNOTE-826 trial.

Health insurance coverage mediated racial and ethnic inequities among patients with advanced-stage cervical cancer, according to findings from a recent retrospective, cross-sectional, population-based study.

The addition of pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) resulted in significantly and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) in women with cervical cancer.

According to results from a recent study, balstilimab, an investigational PD-1 inhibitor, demonstrated meaningful and durable clinical activity in patients with recurrent or metastatic cervical cancer. These findings were presented by Cailin E. Joyce, MD, Director, Applied Technology, Agenus, Boston, MA, during the American Society of Clinical Oncology 2021 virtual annual meeting

Results of a new study investigating the probability of a cervical cancer diagnosis among women aged 65 to 83 years using data from the UK Cervical Screening Call/Recall System indicate that the current practice may need to be changed.